We created an astrocytoma patient survival prediction model consisting of CHI3L1 and OPN expression levels and patient IDH1 mutational status, which predicted two-year astrocytoma patient survival with accuracy rates of 86.8% in all astrocytomas and 93.8% in low-grade astrocytomas (LGG). The gene discussed is SPP1; the disease is astrocytoma (excluding glioblastoma).